XSPRAY — Xspray Pharma publ AB Share News
0.000.00%
Last trade - 00:00- SEK509.25m
- SEK476.65m
Brief: Xspray Pharma Q4 Loss Before Tax Widens To SEK 18.7 Mln
Brief: XSpray Pharma Gets Three New Patents In The U.S. For HyNap-Dasa
Brief: XSpray Pharma Gets Three New Patents In US
Brief: XSpray Pharma Gets New U.S. Patent For HyNap-Dasa
Brief: Xspray Pharma Says Stability Studies With Co's Commercially Manufactured Hynap-Dasa Tablets Began On Feb 11
Brief: Xspray Pharma Has Carried Out A Directed Share Issue Raising Gross Proceeds Of Approximately SEK 122 Mln
Brief: Xspray Pharma Q3 Loss Before Tax At SEK 10.6 Mln
Brief: Xspray Receives FDA Clearance Of IND For HyNap-Dasa
Brief: XSpray Pharma: Successful Submission Of IND Application To FDA
Brief: XSpray Aims For Up-Listing H1 2020
Brief: XSpray Pharma Q2 Pretax Loss At SEK 11.1 Million
Brief: XSpray Gets Additional Product Patents In The United States
Brief: XSpray Pharma Q1 Pre-Tax Loss At SEK 8.5 Million
Brief: Xspray Pharma Announces Positive Clinical Data For Drug Candidate HyNap-Sora
Brief: Xspray Pharma Q4 Operating Loss Widens To SEK 10.5 Million
Brief: XSpray Pharma Gets Additional Product Patent In The US
Brief: Xspray Pharma Q3 Result Before Tax Swings To Loss Of SEK 4.1 Million
Brief: Xspray Pharma Prepares For Listing On Main List
Brief: Xspray Pharma: HyNap-Dasa Shows Formal Bioequivalence